





P-020 ● NMDA RECEPTOR MODULATORS

● D-AP5

● NMDA RECEPTORS



BIOLOGY

The NMDA EPSPs are recorded in the presence of 10 µM NBQX, fully inhibiting AMPA/Kainate component and in a low magnesium solution (0.1 mM). The NMDA competitive antagonist D-AP5 dose dependently inhibits the NMDA-mediated EPSP (See figures) with an IC₅₀ close to 1 µM.

The NMDA EPSP could be measured with a functional or shunted inhibitory interneurons network (in the presence or absence of Picrotoxin).

PATHOLOGIES ASSOCIATED WITH NMDA RECEPTORS

Neurodegenerative diseases (Alzheimer's, Parkinson's and Huntington's Diseases)
Ischemia, Schizophrenia

BIBLIOGRAPHY

- M. R. Foy et al. (1999), J Neurophysiol 81:925-929.
- Duncan, GE et al. (1999) Brain Res. Rev., 29, 250-264.
- Malenka, RC & Nicoll, RA (1999), Science, 285, 1870-1874.
- Samanta, MK et al. (2006), Am. J. Ther., 13, 516-526.
- Bonuccelli, U & Del Dotto, P (2006), Neurology, 67(7 Suppl 2), S30-S38.

Last update: September 16, 2010

electrophysiological testing for the CNS

Domaine de St Hilaire • 595, rue Pierre Berthier • CS 30531 • 13593 AIX EN PROVENCE Cedex 03 • FRANCE
tel: + 33 (0)442 991 220 • fax: +33 (0)442 643 409 • email : contact@neuroservice.com • www.neuroservice.com